Abstract 1574P
Background
The MORM plays a pivotal role in the teaching and learning process for residents, which is crucial for the quality of training received by medical oncology (MO) specialists. However, there is a lack of regulatory framework regarding the system of specialized healthcare training, and anecdotally, there is a lack of definition of time-specific dedication to carry out these responsibilities during the workday, which may lead to resignation and burnout. The objective of this study is to identify, describe and analyze the profile of MORM, assess their capacity for resilience and compare them with a general group of MO. The results of this study will serve as the basis for developing potential resiliency interventions on MORM that may enhance their commitment to the role and prevent burnout.
Methods
Two anonymous online surveys on resilience were conducted among SEOM MO members in 2023. One survey was a general resilience survey sent to MO and the second one was focused on MORM. The results of the questionnaires were compared to identify differential features in both cohorts that could inform about resilience-related actions.
Results
304/3397 (9%) MO and 114/224 (51%) MORM completed the surveys. 95% of the whole population had >5 years-experience, 34% had only an assistant profile and 44% had an assistant profile combined with research activity. An 80% of them spent time working outside work hours and about 50% practiced sports or hobbies ≥ 2 times per week (20% only on weekends and 33% never). More than 80% do not eat properly and sleep less than 7 h/day. Only 34% had a restful sleep during the week. Of note, 61.4% feel undervalued in their mentor’s role. Moreover, 46% of MORM felt anxious due to workload vs 23% of MO, and 73% of MORM arrived on holidays mentally exhausted vs 33% of MO. Despite this, 30% of MORM admit suffering from burnout vs 43% of MO. Interestingly, 77% of MORM believe they have the resources to improve their resilience on themselves vs 62% of MO.
Conclusions
Interventions to help MORMs may be considered to improve work and life balance such as optimizing time spent outside work hours, improving healthy diet or sleeping habits. The management of the organizations must consider these interventions a priority.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Paez: Financial Interests, Personal, Invited Speaker: MSD, Novartis, BMS; Financial Interests, Personal, Advisory Board: Amgen, Esteve, Ipsen; Financial Interests, Personal and Institutional, Research Grant: Merck. M.E. Elez Fernandez: Financial Interests, Personal, Advisory Board: Hoffman La - Roche, Servier, Amgen, Merck Serono, Sanofi, Bayer, Pierre Fabre, MSD, Takeda, Boehringer Ingelheim, Cure Teq AG, Repare Therapeutics Inc., RIN Institute Inc., Janssen; Financial Interests, Personal, Invited Speaker: Organon, Novartis, Pfizer, BMS, Lilly, Medscape; Financial Interests, Personal, Other, Educational training: Seagen International GmbH; Financial Interests, Institutional, Funding: Hoffmann-La Roche Ltd, Sanofi Aventis Recherche & Développement, Amgen Inc., Boehringer Ingelheim, Novartis Farmacéutica SA, Bristol Myers Squibb International Corporation, BeiGene, HalioDX SAS, Janssen-Cilag SA, Merck Health KGAA, Merck Sharp & Dohme de España SA, PharmaMar SA, Servier, Taiho Pharma USA Inc, Hutchison MediPharma International, Menarini, Merus NV, Pfizer, Mirati, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, Celgene International SARL, Debiopharm International SA, Genentech Inc, MedImmune, AbbVie Deutschland Gmbh & Co KG, Bayer Pharma AG, Bioncotech Therapeutics, S.L., Biontech Rna Pharmacuticals GMBH, Biontech Small Molecules GMBH, Boehringer Ingelheim de España S.A., Daiichi Sankyo, Inc, Gercor, Hutchinson Medipharma Limited, Iovance Biotherapeutics, Inc., Janssen Research & Development, Menarini Ricerche SPA, Merck, Sharp & Dohme De España S.A., Nouscom SRL., Pledpharma AB, Redx Pharma PLC, Scandion Oncology, Seattle Genetics Inc., Sotio A.S., Wntresearch AB; Non-Financial Interests, Other, Coordinator of the SEOM +MIR Section of Residents and Young Assistants: Sociedad Española de Oncología Médica (SEOM); Non-Financial Interests, Other, Speaker of the ESMO Academy: European Society for Medical Oncology (ESMO); Non-Financial Interests, Other, Volunteer member of the ASCO Annual Meeting Scientific Program Committee: Developmental Therapeutics – Immunotherapy: American Society of Clinical Oncology (ASCO); Non-Financial Interests, Leadership Role, Member of the Scientific Program Committee and Developmental Therapeutics-Immunotherapy Track Leader, 2023-2024 term: American Society for Clinical Oncology (ASCO); Non-Financial Interests, Other, Member of the Scientific Committee 2024: European Society for Medical Oncology (ESMO); Other, Travel, accommodations, expenses.: Roche, Merck Serono, Sanofi, Amgen, Array BioPharma, Servier, Bristol Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10